1. Scrip
  2. >>Therapy Areas

Fresh Funding Pushes Inflazome Into Clinic With Inflammation Inhibitors

 
• By Jo Shorthouse

With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.

Money and your brain / outline of a man's head with the brain in the shape of money
• Source: Shutterstock

“This could be a new paradigm for treating multiple inflammatory diseases," Matt Cooper, CEO of Inflazome Ltd. told Scrip, when discussing the potential for the company's assets, which are about to enter the clinic in 2019. "And what's exciting is that if it works in several diseases, it may work in several more."

Inflazome is developing in-house small-molecule inhibitors of the NLRP3 inflammasome to stop the cycle of chronic inflammation that drives diseases such as inflammatory bowel disease,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.